Loading clinical trials...
Loading clinical trials...
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria. Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Age
20 - 59 years
Sex
ALL
Healthy Volunteers
No
Pathology Facility
Enugu, Enugu State, Nigeria
University of Nigeria Teaching Hospital
Enugu, Enugu State, Nigeria
Start Date
July 23, 2025
Primary Completion Date
March 31, 2027
Completion Date
September 30, 2027
Last Updated
December 22, 2025
220
ESTIMATED participants
Metformin
DRUG
Placebo
DRUG
Lead Sponsor
University Of Nigeria Teaching Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07460856